Online citations, reference lists, and bibliographies.
← Back to Search

Prognostic Factors In Patients With Pleural Mesothelioma: The European Organization For Research And Treatment Of Cancer Experience.

D. Curran, T. Sahmoud, P. Therasse, J. Van Meerbeeck, P. Postmus, G. Giaccone
Published 1998 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE Identification of prognostic factors in patients with malignant pleural mesothelioma based on prospectively collected international data. PATIENTS AND METHODS From October 1984 to October 1993, 204 eligible adult patients with malignant pleural mesothelioma were entered into five consecutive prospective European Organization for Research and Treatment of Cancer (EORTC) phase II clinical trials designed to assess the efficacy of various anticancer drugs (mitoxantrone, epidoxorubicin, etoposide, and paclitaxel). The Cox model was used to assess 13 factors related to biology and disease history with respect to survival. RESULTS The median survival duration was 12.6 months from diagnosis and 8.4 months from trial entry. In the multivariate analysis, poor prognosis was associated with a poor performance status, a high WBC count, a probable/possible histologic diagnosis of mesothelioma, male gender, and having sarcomatous tissue as the histologic subtype. Taking these five factors into consideration, patients were classified into two groups: a good-prognosis group (1-year survival rate, 40%; 95% confidence interval [CI], 30% to 50%) and a poor-prognosis group (1-year survival, 12%; 95% CI, 4% to 20%). CONCLUSION These results may help to design new clinical trials in pleural mesothelioma by selecting more homogenous groups of patients.
This paper references
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1136/jcp.26.11.832
Epidemiological and quantitative relationships between mesothelioma and asbestos on Tyneside
T. Ashcroft (1973)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
Simian virus 40 and pleural mesothelioma in humans.
H. Strickler (1996)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
10.1002/1097-0142(19921015)70:8<2105::AID-CNCR2820700816>3.0.CO;2-R
Increased secretion of lnterleukin‐6 in malignant mesothelioma cells from a patient with marked thrombocytosis
M. Higashihara (1992)
10.1002/IJC.2910410409
Survival patterns for malignant mesothelioma: The seer experience
R. Spirtas (1988)
10.1002/1097-0142(19930715)72:2<410::AID-CNCR2820720216>3.0.CO;2-G
Prognostic factors of malignant mesothelioma of the pleura.
A. Anand (1994)
10.1200/JCO.1993.11.8.1559
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
A. Chahinian (1993)
10.1200/JCO.1987.5.1.86
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
M. Samson (1987)
10.1200/JCO.1988.6.1.147
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
10.1007/BF00686477
A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy
T. Shinkai (2004)
10.1006/GYNO.1994.1300
Thrombocytosis in surgically treated stage IB squamous cell cervical carcinoma (A Gynecologic Oncology Group study).
E. Hernandez (1994)
10.1111/j.1365-2141.1993.tb04668.x
High IL‐6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer
G. Gastl (1993)
10.5694/J.1326-5377.1954.TB85760.X
Malignant mesothelioma of the pleura.
Sharkey Be (1954)
10.1378/CHEST.93.1.159
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
Harrison's Principles of Internal Medicine
edotir's Eugene Braunwald... (1950)
[The clinical picture and therapy of malignant pleural mesothelioma].
M. Schiebe (1994)
10.1002/1097-0142(19940701)74:1<90::AID-CNCR2820740116>3.0.CO;2-0
Thrombocytosis as a prognostic factor in women with cervical cancer
A. Lopes (1994)
Regression models for prognostic prediction: advantages, problems, and suggested solutions.
F. Harrell (1985)
10.1016/0277-5379(91)90430-L
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
F. J. van Breukelen (1991)
10.1002/SSU.2980100106
Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data.
L. Ries (1994)
10.1200/JCO.1991.9.9.1618
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
K. Albain (1991)
10.2307/2289259
Analysis of Survival Data.
D. Schoenfeld (1986)
The Negative Prognostic Implications of Thrombocytosis in Women With Stage IB Cervical Cancer
G. Rodriguez (1994)
10.1056/NEJM198906293202604
Asbestos-related diseases.
B. Mossman (1989)
10.1093/JNCI/84.22.1731
Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small-cell lung cancer.
M. Graham (1992)
10.1016/S0959-8049(97)00183-4
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
T. Sahmoud (1997)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
10.1038/bjc.1996.465
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
J. Van Meerbeeck (1996)
10.11389/JJRS1963.33.34
[Simultaneous production of parathyroid hormone-related protein (PTHrP) and granulocyte colony-stimulating factor (G-CSF) in lung cancer patients with hypercalcemia and leukocytosis].
A. Sakamoto (1995)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.2307/2987205
Linear Statistical Inference and its Applications
Calyampudi R. Rao (1967)
10.3109/02841869009126536
Blood analyses as prognostic factors in primary lung cancer.
T. Engan (1990)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
10.1016/0169-5002(92)90005-5
Malignant mesothelioma: prognostic factors in a prospective study of 98 patients
L. Tammilehto (1992)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.1002/AJIM.4700030305
Occupational exposure to asbestos: population at risk and projected mortality--1980-2030.
W. Nicholson (1982)
10.1200/JCO.1992.10.5.824
Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
K. Mattson (1992)
10.1038/bjc.1994.20
Constitutive production of multiple colony-stimulating factors in patients with lung cancer associated with neutrophilia.
N. Adachi (1994)
10.7326/0003-4819-87-5-613
Pleural mesothelioma: clinical features and therapeutic implications.
S. Legha (1977)
10.1016/S0025-6196(12)65411-1
Malignant mesothelioma of the pleura.
R. J. Pisani (1988)
10.1007/978-1-4612-4380-9_37
Regression Models and Life-Tables
D. Cox (1972)
10.1165/AJRCMB.12.5.7742009
The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma.
D. FitzPatrick (1995)
10.1136/thx.51.11.1074
Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue.
C. Pepper (1996)
Production of interleukin-6 from macrophages by MDP-Lys (L 18), romurtide.
K. Shimoda (1990)
10.1038/bjc.1994.192
Statistical aspects of prognostic factor studies in oncology.
R. Simon (1994)
10.1200/JCO.1993.11.6.1172
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
10.1378/CHEST.107.6_SUPPLEMENT.332S
Current approach to malignant mesothelioma of the pleura.
J. Aisner (1995)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1056/NEJM198007243030407
Current concepts: malignant mesothelioma.
K. Antman (1980)
Adjuvant therapy for malignant pleural mesothelioma.
Keller Sm (1994)
10.1002/1097-0142(19920615)69:12<2975::AID-CNCR2820691218>3.0.CO;2-A
Poor prognosis associated with thrombocytosis in patients with cervical cancer
E. Hernandez (1992)



This paper is referenced by
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
Stratification of Malignant Pleural Mesothelioma Prognosis Using
Hidekazu SuzukiKazuhiro (2014)
10.5798/dicletip.705798
The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma
N. Akdeniz (2020)
10.1016/J.LUNGCAN.2006.11.005
A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience.
M. Metintas (2007)
10.1002/9780470025079.CHAP49.PUB2
Pleura and Peritoneum
M. Sheaff (2007)
10.2217/fon.15.274
The MesoVATS trial: is there a future for video-assisted thoracoscopic surgery partial pleurectomy?
R. Rintoul (2015)
10.21037/atm.2017.06.60
Diagnosis and prognosis-review of biomarkers for mesothelioma.
H. H. Sun (2017)
10.1007/978-3-030-18944-0_7
Malignant Pleural Effusions and Mesothelioma
D. Cooper (2019)
10.2147/TCRM.S104077
Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?
Seda Tural Onur (2016)
10.1016/j.lungcan.2017.09.012
External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
Yuki Kataoka (2017)
10.1016/J.LUNGCAN.2006.09.023
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
C. Obasaju (2007)
10.1007/0-387-31056-8_38
Therapy for malignant pleural mesothelioma
H. Pass (2006)
Mesothelioma in 2010 Mesothéliome en 2010
Y. Aelony (2011)
10.1016/j.ctrv.2012.12.005
Malignant mesothelioma: new insights into a rare disease.
J. Remon (2013)
10.1046/j.1365-2362.2000.00632.x
Intrapleural administration of tumour necrosis factor‐alpha (TNFα) in patients with mesothelioma: cytokine patterns and acute‐phase protein response
Stam (2000)
10.1136/bmjresp-2017-000240
Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors
A. Kidd (2018)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.3322/caac.21572
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
10.1038/bjc.2013.130
Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma
R. Mezzapelle (2013)
10.1016/j.lungcan.2008.01.013
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
K. Ribi (2008)
10.1016/j.lungcan.2008.09.008
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
C. Lee (2009)
10.1097/00001622-200303000-00006
Chemotherapy for malignant pleural mesothelioma
S. Tomek (2003)
10.1016/B978-0-323-05905-3.00006-6
6 – Malignant Mesothelioma
P. Jänne (2010)
preoperative assessment of patients with malignant pleural mesothelioma The value of chest computer tomography and cervical mediastinoscopy in the
Nico van Zandwijk (2013)
10.4172/2329-9126.1000245
Hyponatremia: A Potential Prognostic Biomarker in Malignant Pleural Mesothelioma?
Zoe Hudson (2016)
10.3978/j.issn.2072-1439.2015.11.15
Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.
T. Tagawa (2015)
10.1016/j.lungcan.2009.06.014
Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice.
C. Lee (2009)
Angiogenesis, cyclooxygenase-2 and matrix metalloproteinases in malignant mesothelioma
J. Edwards (2003)
10.1136/thx.2007.081430
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
A. Chapman (2008)
10.1007/978-3-030-18944-0
Integrated Palliative Care of Respiratory Disease
S. Bourke (2019)
10.12688/f1000research.15512.3
Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort
W. Amin (2018)
10.1016/j.molonc.2014.11.007
MiR‐Score: A novel 6‐microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma
M. Kirschner (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar